178 related articles for article (PubMed ID: 9523662)
21. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.
Freedland SJ; Terris MK; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Aronson WJ;
J Urol; 2004 Jun; 171(6 Pt 1):2215-20. PubMed ID: 15126788
[TBL] [Abstract][Full Text] [Related]
22. Intraductal carcinoma of the prostate in prostate biopsy samples: correlation with aggressive pathological features after radical prostatectomy and prognostic value in high-risk prostate cancer.
Zhu S; Zhao JG; Chen JR; Liu ZH; Sun GX; Wang ZP; Ni YC; Dai JD; Shen PF; Zeng H
Asian J Androl; 2020; 22(5):519-525. PubMed ID: 31710002
[TBL] [Abstract][Full Text] [Related]
23. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.
Khani F; Epstein JI
Am J Surg Pathol; 2015 Oct; 39(10):1383-9. PubMed ID: 26076065
[TBL] [Abstract][Full Text] [Related]
24. Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer.
Huang JG; Pedersen J; Hong MK; Harewood LM; Peters J; Costello AJ; Hovens CM; Corcoran NM
BJU Int; 2013 May; 111(6):921-7. PubMed ID: 23350712
[TBL] [Abstract][Full Text] [Related]
25. Should we replace the Gleason score with the amount of high-grade prostate cancer?
Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
[TBL] [Abstract][Full Text] [Related]
26. Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions.
Miyai K; Divatia MK; Shen SS; Miles BJ; Ayala AG; Ro JY
Int J Clin Exp Pathol; 2014; 7(5):2518-26. PubMed ID: 24966964
[TBL] [Abstract][Full Text] [Related]
27. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
[TBL] [Abstract][Full Text] [Related]
28. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
29. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
[TBL] [Abstract][Full Text] [Related]
30. [SIGNIFICANCE OF INTRADUCTAL CARCINOMA OF THE PROSTATE IN POST-OPERATIVE BIOCHEMICAL RECURRENCE].
Sakamoto N; Ueda S; Mizoguchi H; Kawahara I; Kobayashi T; Hamaguchi M; Yoshikawa M
Nihon Hinyokika Gakkai Zasshi; 2017; 108(1):5-11. PubMed ID: 29367511
[TBL] [Abstract][Full Text] [Related]
31. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
32. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
[TBL] [Abstract][Full Text] [Related]
33. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
[TBL] [Abstract][Full Text] [Related]
34. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
35. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.
San Francisco IF; Regan MM; Olumi AF; DeWolf WC
J Urol; 2004 Apr; 171(4):1492-9. PubMed ID: 15017206
[TBL] [Abstract][Full Text] [Related]
36. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
37. Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy.
Freedland SJ; Csathy GS; Dorey F; Aronson WJ
Urology; 2002 Jul; 60(1):84-8. PubMed ID: 12100929
[TBL] [Abstract][Full Text] [Related]
38. Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.
Tosoian JJ; Chappidi M; Feng Z; Humphreys EB; Han M; Pavlovich CP; Epstein JI; Partin AW; Trock BJ
BJU Int; 2017 May; 119(5):676-683. PubMed ID: 27367645
[TBL] [Abstract][Full Text] [Related]
39. High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy.
Pierorazio PM; Lambert SM; Matsukhani M; Sprenkle PC; McCann TR; Katz AE; Olsson CA; Benson MC; McKiernan JM
BJU Int; 2007 Nov; 100(5):1066-70. PubMed ID: 17784880
[TBL] [Abstract][Full Text] [Related]
40. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
